𝔖 Bobbio Scriptorium

✦ LIBER ✦

EORTC study shows LHRH-agonist added to Tamoxifen improves premenopausal patients survival in metastatic breast cancer

Book ID: 117664249
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 116 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)81970-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PP-8-1 Combined estroyen suppression and

PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881)

✍ J.G.M. Klijn; C. Seynaeve; L. Beex; L. Mauriac; J. van Zijl; C. Veyret; J. Wildi 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Intermittent/alternated therapy with tam

Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863)

✍ L Beex; C Rose; H Mouridsen; J Jassem; M Nooy; J Estape; R Paridaens; M.J Piccar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Adding androgen suppression to radiother

Adding androgen suppression to radiotherapy may improve disease-free survival over radiotherapy alone in locally advanced prostate cancer: Abstracted from: Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6.

✍ John B Fiveash 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB